Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Bristol Myers Squibb 4Q Revenues up 1% | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Bristol Myers Squibb 4Q Revenues up 1%

Higher sales of new product portfolio, as well as Eliquis and Opdivo sales, were partially offset by lower sales of Revlimid.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Bristol Myers Squibb
4Q Revenues: $11.5 billion (+1%) 
4Q Earnings: $1.8 billion (-13%)
FY Revenues: $45.0 billion (-2%) 
FY Earnings: $8.0 billion (+27%)
Comments: Higher sales of new product portfolio, as well as Eliquis and Opdivo sales, were partially offset by lower sales of Revlimid, down 38% to $1.5 billion. Total In-Line Products were up 5% to $8.7 billion. Eliquis sales were $2.9 billion in the quarter, up 7%. Opdivo sales were $2.4 billion, up 8%. Orencia sales were $985 million, up 8%. Pomalyst/Imnovid sales were $890 million, up 1%. Yervoy sales were flat at $566 million. Sprycel sales were $526 million, down 9%. New product portfolio sales were up 66% to $645 million. Reblozyl sales were up 61% to $199 million. Opdualag sales were up 83% to $104 million. Zeposia sales were up 68% to $133 million, and Breyanzi sales were up 84% to $55 million.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters